In 2023, updated data from Huye district, Rwanda revealed that 17.5% of malaria patients exhibited markers for artemisinin resistance, nearly doubling from 2019.
Markers for lumefantrine tolerance, specifically N86, approached a fixation rate of 98%.
Overall, while resistance markers for both artemisinin and lumefantrine are on the rise, the increase is happening at a relatively slow pace in southern Rwanda.